Patents by Inventor Marco A. Passini

Marco A. Passini has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240350584
    Abstract: Compositions and methods for treating disorders affecting motor function, such as motor function affected by disease or injury to the brain and/or spinal cord, are disclosed.
    Type: Application
    Filed: March 26, 2024
    Publication date: October 24, 2024
    Applicant: Genzyme Corporation
    Inventors: Marco A. PASSINI, Lamya Shihabuddin, Seng H. Cheng
  • Patent number: 12121532
    Abstract: The present disclosure relates to modified antisense oligomers and related compositions and methods for increasing the expression of functional SMN protein and methods for treating spinal muscular atrophy and relates to inducing inclusion of exon 7 in SMN2 mRNA.
    Type: Grant
    Filed: November 23, 2020
    Date of Patent: October 22, 2024
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Marco A. Passini, Gunnar J. Hanson
  • Publication number: 20240238326
    Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.
    Type: Application
    Filed: October 25, 2023
    Publication date: July 18, 2024
    Applicants: Biogen MA Inc., Cold Spring Harbor Laboratory
    Inventors: C. Frank Bennett, Gene Hung, Frank Rigo, Adrian R. Krainer, Yimin Hua, Marco A. Passini, Lamya Shihabuddin, Seng H. Cheng, Katherine W. Klinger
  • Patent number: 11975043
    Abstract: Compositions and methods for treating disorders affecting motor function, such as motor function affected by disease or injury to the brain and/or spinal cord, are disclosed.
    Type: Grant
    Filed: October 13, 2022
    Date of Patent: May 7, 2024
    Assignee: Genzyme Corporation
    Inventors: Marco A. Passini, Lamya Shihabuddin, Seng H. Cheng
  • Patent number: 11957765
    Abstract: The disclosure pertains to methods and compositions for treating disorders affecting the central nervous system (CNS). These disorders include neurometabolic disorders such as lysosomal storage diseases that affect the central nervous system, e.g., Niemann-Pick A disease. They also include disorders such as Alzheimer's disease. The disclosed methods involve contacting an axonal ending of a neuron with a composition containing high titer AAV carrying a therapeutic transgene so that the AAV vector is axonally transported in a retrograde fashion and transgene product is expressed distally to the administration site.
    Type: Grant
    Filed: March 3, 2020
    Date of Patent: April 16, 2024
    Assignee: Genzyme Corporation
    Inventors: Marco A. Passini, James Dodge
  • Patent number: 11911440
    Abstract: Compositions and methods for treating disorders affecting motor function, such as motor function affected by disease or injury to the brain and/or spinal cord, are disclosed.
    Type: Grant
    Filed: November 10, 2022
    Date of Patent: February 27, 2024
    Assignee: Genzyme Corporation
    Inventors: Marco A. Passini, Lamya Shihabuddin, Seng H. Cheng
  • Publication number: 20240033323
    Abstract: Compositions and methods for treating disorders affecting motor function, such as motor function affected by disease or injury to the brain and/or spinal cord, are disclosed.
    Type: Application
    Filed: October 17, 2023
    Publication date: February 1, 2024
    Applicant: Genzyme Corporation
    Inventors: Marco A. PASSINI, Lamya Shihabuddin, Seng H. Cheng
  • Publication number: 20240000886
    Abstract: The present provides methods for treating spinal muscular atrophy using a self-complementary recombinant adeno-associated virus (rAAV) viral particle comprising a transgene expressing SMN. In one aspect, the viral particles are administered in the spinal column or cisterna magna in a human subject; for example, a pediatric human subject. Viral particles comprising AAV9 capsids are contemplated.
    Type: Application
    Filed: April 21, 2023
    Publication date: January 4, 2024
    Applicant: Genzyme Corporation
    Inventors: Marco A. Passini, Lamya S. Shihabuddin, Catherine R. O'Riordan, Seng H. Cheng
  • Publication number: 20230381216
    Abstract: Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 51 skipping are described.
    Type: Application
    Filed: March 9, 2023
    Publication date: November 30, 2023
    Applicant: Sarepta Therapeutics, Inc.
    Inventors: Marco A. PASSINI, Gunnar J. HANSON
  • Publication number: 20230287366
    Abstract: This disclosure pertains to methods and compositions for tolerizing a mammal's brain to exogenously administered acid sphingomyelinase polypeptide by first delivering an effective amount of a transgene encoding the polypeptide to the mammal's hepatic tissue and then administering an effective amount of the transgene to the mammal's central nervous system (CNS).
    Type: Application
    Filed: March 8, 2023
    Publication date: September 14, 2023
    Inventors: Marco A. PASSINI, Robin J. ZIEGLER, James C. DODGE, Lamya SHIHABUDDIN, Seng H. CHENG
  • Publication number: 20230242909
    Abstract: The present invention relates to compositions and methods for treating neurodegeneration and neurodegenerative diseases associated with axonal degeneration. Neurodegeneration and neurodegenerative diseases associated with axonal degeneration are treated with therapies comprising SARM1 inhibitors such as SARM1 antisense oligonucleotides.
    Type: Application
    Filed: November 25, 2020
    Publication date: August 3, 2023
    Inventors: Liza LEVENTHAL, Thomas ENGBER, Raul Eduardo KRAUSS, Rajesh DEVRAJ, Robert Owen HUGHES, Todd BOSANAC, Sudhir AGRAWAL, Marco A. PASSINI
  • Patent number: 11642364
    Abstract: Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 51 skipping are described.
    Type: Grant
    Filed: May 4, 2022
    Date of Patent: May 9, 2023
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Marco A. Passini, Gunnar J. Hanson
  • Publication number: 20230135379
    Abstract: Compositions and methods for treating disorders affecting motor function, such as motor function affected by disease or injury to the brain and/or spinal cord, are disclosed.
    Type: Application
    Filed: November 10, 2022
    Publication date: May 4, 2023
    Applicant: Genzyme Corporation
    Inventors: Marco A. PASSINI, Lamya Shihabuddin, Seng H. Cheng
  • Publication number: 20230110479
    Abstract: Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 52 skipping are described.
    Type: Application
    Filed: April 27, 2022
    Publication date: April 13, 2023
    Applicant: Sarepta Therapeutics, Inc.
    Inventors: Gunnar J. HANSON, Marco A. PASSINI, Frederick Joseph SCHNELL
  • Publication number: 20230084580
    Abstract: Compositions and methods for treating disorders affecting motor function, such as motor function affected by disease or injury to the brain and/or spinal cord, are disclosed.
    Type: Application
    Filed: October 13, 2022
    Publication date: March 16, 2023
    Applicant: Genzyme Corporation
    Inventors: Marco A. PASSINI, Lamya Shihabuddin, Seng H. Cheng
  • Publication number: 20220387601
    Abstract: Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 45 skipping are described.
    Type: Application
    Filed: May 26, 2022
    Publication date: December 8, 2022
    Applicant: Sarepta Therapeutics, Inc.
    Inventors: Marco A. PASSINI, Gunnar J. HANSON
  • Publication number: 20220370348
    Abstract: Neurological diseases, including lysosomal storage diseases, can be successfully treated using intraventricular delivery of the therapeutic agents to bypass the blood-brain barrier. Similarly, diagnostic agents and anesthetic agents can be delivered to the brain in this manner. The administration can be performed slowly to achieve maximum effect. Such administration permits greater penetration of distal portions of the brain.
    Type: Application
    Filed: January 10, 2022
    Publication date: November 24, 2022
    Inventors: James C. DODGE, Marco A. PASSINI, Lamya S. SHIHABUDDIN, Seng H. CHENG
  • Publication number: 20220280546
    Abstract: Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 51 skipping are described.
    Type: Application
    Filed: May 4, 2022
    Publication date: September 8, 2022
    Applicant: Sarepta Therapeutics, Inc.
    Inventors: Marco A. PASSINI, Gunnar J. HANSON
  • Publication number: 20220251551
    Abstract: Antisense oligomers complementary to a selected target site in the human dystrophin gene to induce exon 51 skipping are described.
    Type: Application
    Filed: June 12, 2019
    Publication date: August 11, 2022
    Applicant: Sarepta Therapeutics, Inc.
    Inventors: Frederick Joseph SCHNELL, Marco PASSINI, Nelsa ESTRELLA, Gunnar HANSON, Ming ZHOU, Richard BESTWICK
  • Patent number: 11395855
    Abstract: Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.
    Type: Grant
    Filed: April 30, 2021
    Date of Patent: July 26, 2022
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Marco A. Passini, Gunnar J. Hanson